Security
PRRUF · IMMUTEP Ltd
PRRUFOTCCommon stockCurrentCIK 1506184Updated Sep 26, 2026
Name history
Prima BioMed Ltd · through Dec 1, 2017
PRRUF price & chart
Loading TradingView…
OTC:PRRUF on TradingView ↗About the company
Immutep is a late-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease. The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit www.immutep.com.
In the news
No coverage from other publishers is available.
Recent filings
Show 5 more recent filings
Financials
FY 2025 · AUDSource
Source
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Profit or LossAUD | -61,434,165Source | -42,716,625Source | -39,896,348Source | -32,210,826Source |
| Additional Financial Items | ||||
| AdjustmentsForCurrentTaxOfPriorPeriodAUD | — | — | — | 148,303Source |
| AdjustmentsForSharebasedPaymentsAUD | 1,163,543Source | 1,796,286Source | 2,001,572Source | 1,486,841Source |
| AdjustmentsForUnrealisedForeignExchangeLossesGainsAUD | 3,165,899Source | -283,057Source | -296,038Source | — |
| GeneralAndAdministrativeExpenseAUD | 8,644,503Source | 8,852,615Source | 8,679,840Source | 7,210,123Source |
| IncomeTaxesPaidRefundClassifiedAsOperatingActivitiesAUD | 0Source | 0Source | 0Source | 34Source |
| InterestPaidClassifiedAsFinancingActivitiesAUD | 36,759Source | 30,328Source | 8,818Source | 9,712Source |
| InterestPaidClassifiedAsOperatingActivitiesAUD | 35,545Source | 30,009Source | 20,541Source | — |
| InterestReceivedClassifiedAsOperatingActivitiesAUD | 3,716,331Source | 3,695,594Source | 917,997Source | 224,656Source |
| PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivitiesAUD | 270,666Source | 226,494Source | 211,974Source | 222,536Source |
| PurchaseOfIntangibleAssetsClassifiedAsInvestingActivitiesAUD | 225,414Source | 903,154Source | — | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueAUD | 10,331,373Source | 7,838,625Source | 5,200,128Source | 6,758,073Source |
| Additional Financial Items | ||||
| AdministrativeExpenseAUD | 3,554,058Source | 4,229,578Source | 3,711,789Source | 3,321,923Source |
| BasicEarningsLossPerShareAUD/shares | -0.04Source | -0.04Source | -0.04Source | -0.04Source |
| CurrentTaxExpenseIncomeAUD | — | — | — | 34Source |
| DeferredTaxExpenseIncomeAUD | — | — | — | 0Source |
| DeferredTaxExpenseIncomeRecognisedInProfitOrLossAUD | 0Source | 0Source | 0Source | 0Source |
| DepreciationAndAmortisationExpenseAUD | 2,389,524Source | 2,261,858Source | 2,061,819Source | 2,063,462Source |
| DepreciationRightofuseAssetsAUD | 255,110Source | 248,764Source | 202,605Source | 224,406Source |
| DilutedEarningsLossPerShareAUD/shares | -0.04Source | -0.04Source | -0.04Source | -0.04Source |
| EmployeeBenefitsExpenseAUD | 10,772,257Source | 8,824,161Source | 6,527,725Source | 4,966,304Source |
| ExpenseFromSharebasedPaymentTransactionsWithEmployeesAUD | 1,163,543Source | 1,796,286Source | 2,001,572Source | 1,486,841Source |
| ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsedAUD | 5,580Source | 4,705Source | 5,782Source | 9,518Source |
| ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsedAUD | 3,216Source | 3,165Source | 6,539Source | 2,376Source |
| FinanceCostsAUD | 37,078Source | 30,594Source | 20,401Source | 92,430Source |
| GeneralAndAdministrativeExpenseAUD | 8,644,503Source | 8,852,615Source | 8,679,840Source | 7,210,123Source |
| IncomeTaxExpenseContinuingOperationsAUD | 0Source | 0Source | 0Source | 34Source |
| InterestExpenseOnLeaseLiabilitiesAUD | 36,283Source | 30,272Source | 8,678Source | 10,462Source |
| NetForeignExchangeLossAUD | 1,529,309Source | — | 0Source | 0Source |
| ProfitLossAttributableToOwnersOfParentAUD | -61,434,165Source | -42,716,625Source | -39,896,348Source | -32,210,826Source |
| ProfitLossBeforeTaxAUD | -61,434,165Source | -42,716,625Source | -39,896,348Source | -32,210,792Source |
| ResearchAndDevelopmentExpenseAUD | 49,778,916Source | 31,472,063Source | 28,793,385Source | 25,337,538Source |
| RevenueFromInterestAUD | 5,287,209Source | 3,882,757Source | 938,999Source | 224,520Source |
Filing attachments
d79097dex991.htm · 6-K · 2026-09-22
Exhibit 99.1 Change to American Depositary Share Ratio SYDNEY, AUSTRALIA - September 21, 2026 - Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces a change to the ratio of its American Depositary Shares (“ADSs”), which are quoted on the Nasdaq Global Market under the symbol IMMP. With effect from the commencement of trading on the Nasdaq Global Market on 28 September 2026 (US Easte…
Read attachment ↗